Table 3.

Western blot analysis: treatment effect within gender^a and gender^b differences[ratio of values in Table 2 (soluble/insoluble)]

	Ratio (soluble/insoluble)
	PHF1	MC1
	M	F	M	F
2–5 months
Tg control	0.83 ± 0.14	2.04 ± 0.41++	0.76 ± 0.15	0.16 ± 0.04++
Tg Phos-tau	2.72 ± 0.62**	2.36 ± 0.50	1.55 ± 0.90	0.36 ± 0.11
2–8 months
Tg control	4.26 ± 1.19	1.00 ± 0.38+	5.73 ± 1.64	2.07 ± 0.88
Tg Phos-tau	2.98 ± 0.61	1.31 ± 0.45	5.20 ± 1.39	0.83 ± 0.34++

^aTreatment effect within gender: In the 2−5 month study, the ratio of soluble/insoluble tau differed between treated and control mice in PHF1 blots for males. **p ≤ 0.01, significantly different from control mice within the same gender.

^bGender differences: In the 2−5 month study, male (n = 8) and female (n = 6) controls differed in tau ratio (soluble/insoluble; PHF1 and MC1) but not Phos-tau-immunized males (n = 5) and females (n = 7). A similar pattern was observed in the immunohistochemical analysis with differences only observed in control groups. In the 2−8 month study (six males and six females per group), this difference was not as group specific with differences observed in tau ratio (soluble/insoluble; PHF1) within controls and in the Phos-tau-immunized mice (MC1). ⁺p ≤ 0.05, ⁺⁺p ≤ 0.01, significantly different from males within the same treatment group.